keyword
MENU ▼
Read by QxMD icon Read
search

primary peritoneal cancer

keyword
https://www.readbyqxmd.com/read/28105356/conversion-therapy-for-pancreatic-cancer-with-peritoneal-metastases-using-intravenous-and-intraperitoneal-paclitaxel-with-s-1
#1
Hiromitsu Kitayama, Yasushi Tsuji, Tomohiro Kondo, Junko Sugiyama, Michiaki Hirayama, Kazuyuki Yamamoto, You Kawarada, Yumiko Oyamada, Satoshi Hirano
Combination chemotherapy consisting of systemic and intraperitoneal agents against peritoneal metastases from several types of cancer has shown promising results. We herein report a case in which combination therapy with intravenous and intraperitoneal paclitaxel with S-1 converted an unresectable pancreatic cancer with peritoneal metastases into a resectable one. The patient was a 65-year old woman with recurrent pancreatitis for 5 months. Endoscopic ultrasonography-guided fine-needle aspiration revealed minute epithelial masses composed of cells with irregular nuclei in the pancreatic body...
December 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28105352/conversion-therapy-of-gastric-cancer-with-massive-malignant-ascites-and-ovarian-metastases-by-systemic-and-intraperitoneal-chemotherapy
#2
Tomohiro Kondo, Hiromitsu Kitayama, Junko Sugiyama, Michiaki Hirayama, Yoshinori Suzuki, Yumiko Oyamada, Yasushi Tsuji
Intravenous and intraperitoneal paclitaxel with S-1 is showing promising results in gastric cancer with peritoneal metastases. We herein report a successful conversion of unresectable to resectable disease using combination chemotherapy with trastuzumab. The patient was a 39-year-old woman with human epidermal growth factor receptor 2-positive gastric cancer with peritoneal, pulmonary and bilateral ovarian metastases. After 6 cycles of S-1 plus cisplatin with trastuzumab, followed by 15 cycles of intravenous and intraperitoneal paclitaxel with S-1 and trastuzumab, the pulmonary and peritoneal metastases exhibited complete response and no evidence of malignancy was found on diagnostic laparoscopy...
December 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28103611/phase-ii-randomised-discontinuation-trial-of-the-met-vegf-receptor-inhibitor-cabozantinib-in-metastatic-melanoma
#3
Adil Daud, Harriet M Kluger, Razelle Kurzrock, Frauke Schimmoller, Aaron L Weitzman, Thomas A Samuel, Ali H Moussa, Michael S Gordon, Geoffrey I Shapiro
BACKGROUND: A phase II randomised discontinuation trial assessed cabozantinib (XL184), an orally bioavailable inhibitor of tyrosine kinases including VEGF receptors, MET, and AXL, in a cohort of patients with metastatic melanoma. METHODS: Patients received cabozantinib 100 mg daily during a 12-week lead-in. Patients with stable disease (SD) per Response Evaluation Criteria in Solid Tumours (RECIST) at week 12 were randomised to cabozantinib or placebo. Primary endpoints were objective response rate (ORR) at week 12 and postrandomisation progression-free survival (PFS)...
January 19, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28099523/the-role-of-liquid-based-cytology-and-ancillary-techniques-in-the-peritoneal-washing-analysis-our-institutional-experience
#4
Esther Rossi, Tommaso Bizzarro, Maurizio Martini, Adhemar Longatto-Filho, Fernando Schmitt, Anna Fagotti, Giovanni Scambia, Gian Franco Zannoni
BACKGROUND: The cytological analysis of peritoneal effusions serves as a diagnostic and prognostic aid for either primary or metastatic diseases. Among the different cytological preparations, liquid based cytology (LBC) represents a feasible and reliable method ensuring also the application of ancillary techniques (i.e immunocytochemistry-ICC and molecular testing). METHODS: We recorded 10348 LBC peritoneal effusions between January 2000 and December 2014. They were classified as non-diagnostic (ND), negative for malignancy-NM, atypical-suspicious for malignancy-SM and positive for malignancy-PM...
2017: PloS One
https://www.readbyqxmd.com/read/28089377/phase-ii-trial-of-albumin-bound-paclitaxel-and-granulocyte-macrophage-colony-stimulating-factor-as-an-immune-modulator-in-recurrent-platinum-resistant-ovarian-cancer
#5
John B Liao, Ron E Swensen, Kelsie J Ovenell, Katie M Hitchcock-Bernhardt, Jessica L Reichow, Minjun C Apodaca, Leonard D'Amico, Jennifer S Childs, Doreen M Higgins, Barbara J Buening, Barbara A Goff, Mary L Disis
BACKGROUND: Granulocyte macrophage colony-stimulating factor (GM-CSF) stimulates immunity via recruitment of antigen presenting cells and tumor specific T-cell stimulation. Albumin-bound paclitaxel (nab-paclitaxel) followed by GM-CSF may enhance antitumor responses and prolong remissions in ovarian cancer. Immune phenotypes present before treatment may identify responders to chemo-immunotherapy. METHODS: Recurrent platinum-resistant ovarian, peritoneal, or fallopian tube cancer patients received nab-paclitaxel, 100mg/m(2) days 1, 8, 15 followed by GM-CSF 250μg days 16-26 every 28days for 6 planned cycles...
January 12, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28089376/chemotherapy-completion-in-elderly-women-with-ovarian-primary-peritoneal-or-fallopian-tube-cancer-an-nrg-oncology-gynecologic-oncology-group-study
#6
Vivian E von Gruenigen, Helen Q Huang, Jan H Beumer, Heather A Lankes, William Tew, Thomas Herzog, Arti Hurria, Robert S Mannel, Tina Rizack, Lisa M Landrum, Peter G Rose, Ritu Salani, William H Bradley, Thomas J Rutherford, Robert V Higgins, Angeles Alvarez Secord, Gini Fleming
PURPOSE: A simple measure to predict chemotherapy tolerance in elderly patients would be useful. We prospectively tested the association of baseline Instrumental Activities of Daily Living (IADL) score with ability to complete 4 cycles of first line chemotherapy without dose reductions or >7days delay in elderly ovarian cancer patients. PATIENTS AND METHODS: Patients' age ≥70 along with their physicians chose between two regimens: CP (Carboplatin AUC 5, Paclitaxel 135mg/m(2)) or C (Carboplatin AUC 5), both given every 3weeks either after primary surgery or as neoadjuvant chemotherapy (NACT) with IADL and quality of life assessments performed at baseline, pre-cycle 3, and post-cycle 4...
January 12, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28076472/evaluation-of-lymphatic-spread-visceral-metastasis-and-tumoral-local-invasion-in-esophageal-carcinomas
#7
Francisco Tustumi, Cintia Mayumi Sakurai Kimura, Flavio Roberto Takeda, Rubens Antônio Aissar Sallum, Ulysses Ribeiro-Junior, Ivan Cecconello
Background: Knowing esophageal tumors behavior in relationship to lymph node involvement, distant metastases and local tumor invasion is of paramount importance for the best esophageal tumors management. Aim: To describe lymph node involvement, distant metastases, and local tumor invasion in esophageal carcinoma, according to tumor topography and histology. Methods: A total of 444 patients with esophageal squamous cell carcinoma and 105 adenocarcinoma were retrospectively analyzed...
November 2016: Arquivos Brasileiros de Cirurgia Digestiva: ABCD, Brazilian Archives of Digestive Surgery
https://www.readbyqxmd.com/read/28073597/en-bloc-resection-of-the-pelvis-enbrp-in-patients-with-stage-iiic-iv-ovarian-cancer-a-10-steps-standardised-technique-surgical-and-survival-outcomes-of-primary-vs-interval-surgery
#8
Roberto Tozzi, Kieran Hardern, Kumar Gubbala, Riccardo Garruto Campanile, Hooman Soleymani Majd
OBJECTIVE: In this study we describe the technique of the En-bloc resection of the pelvis (EnBRP) in 10 standardised and reproducible steps, whereby all pelvic organs, except the bladder, are removed together with the peritoneum. In addition, we compare the surgical and survival outcomes of patients who underwent upfront vs. interval surgery. METHODS: Retrospective analysis of patients with FIGO Stage IIIC-IV ovarian cancer treated with Visceral Peritoneal Debulking (VPD) who had EnBRP...
January 7, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28061769/intraperitoneal-cisplatin-and-doxorubicin-as-maintenance-chemotherapy-for-unresectable-ovarian-cancer-a-case-report
#9
Clemens B Tempfer, Franziska Hartmann, Ziad Hilal, Günther A Rezniczek
BACKGROUND: Primary advanced, unresectable ovarian cancer (OC) is treated with palliative systemic chemotherapy. Intraperitoneal chemotherapy may be an alternative local maintenance therapy. CASE PRESENTATION: A 75 year old woman with laparoscopically and histologically confirmed unresectable OC was treated with 13 cycles of intraperitoneal cisplatin 7.5 mg/m(2) and doxorubicin 1.5 mg/m(2) over 2 years using laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC)...
January 6, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28060918/the-impact-of-the-duration-of-adjuvant-chemotherapy-on-survival-in-patients-with-epithelial-ovarian-cancer-a-retrospective-study
#10
Veronika Seebacher, Alexander Reinthaller, Heinz Koelbl, Nicole Concin, Regina Nehoda, Stephan Polterauer
OBJECTIVE: The aim of the present study was to investigate the prognostic role of the duration of adjuvant chemotherapy in patients with epithelial ovarian, fallopian tube and primary peritoneal cancer (EOC). MATERIALS AND METHODS: Within the present study we retrospectively evaluated the data of 165 consecutive patients with EOC treated with primary surgery followed by six completed cycles of platinum-taxan based intravenous adjuvant chemotherapy. Medians of total duration of chemotherapy were compared with clinical-pathological parameters...
2017: PloS One
https://www.readbyqxmd.com/read/28058561/percutaneous-peritoneal-lavage-for-the-rapid-staging-of-gastric-and-pancreatic-cancer
#11
Linda M Pak, Daniel G Coit, Anne A Eaton, Peter J Allen, Michael I D'Angelica, Ronald P DeMatteo, William R Jarnagin, Vivian E Strong, T Peter Kingham
BACKGROUND: Positive peritoneal cytology is classified as M1 disease in gastric and pancreatic cancer. While peritoneal cytology is typically obtained by laparoscopic peritoneal lavage, this study sought to examine the feasibility and safety of performing this percutaneously, with monitored anesthesia care and in combination with other diagnostic procedures to condense and expedite the staging process. METHODS: Patients with gastric or pancreatic cancer scheduled for laparoscopy with peritoneal lavage were prospectively enrolled to undergo intraoperative percutaneous peritoneal lavage prior to laparoscopic peritoneal lavage...
January 5, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28054141/indications-for-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-in-elderly-patients-with-peritoneal-malignancy
#12
Toshiyuki Kitai, Kenya Yamanaka, Yuya Miyauchi, Masahiro Kawashima
PURPOSE: A combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) is effective for some peritoneal malignancies. However, the indications for elderly patients remain unclear, with substantial postoperative morbidity and mortality being problematic. MATERIALS: Clinical data were analyzed in 42 patients undergoing CRS + HIPEC for peritoneal malignancy. The primary tumor was located in the appendix in 32 cases and elsewhere in 10 cases...
January 4, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28052691/strategies-to-prevent-peritoneal-carcinomatosis-arising-from-colorectal-cancer
#13
Maximiliano Gelli, Janina Fl Hugueinin, Cecilia Cerebelli, Léonor Benhaim, Charles Honoré, Dominique Elias, Diane Goéré
In the last decades, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy became a curative option for peritoneal metastases in selected patients, otherwise considered for palliative therapy alone. Better knowledge of physiopathology of peritoneal spread and identification of predictive factors for peritoneal relapse prompted specialized centers to investigate the role of a 'proactive approach' in order to early detect peritoneal metastasis. These encouraging data could justify an active attitude in selected patients at high risk of peritoneal recurrence after curative resection of primary tumor...
January 5, 2017: Future Oncology
https://www.readbyqxmd.com/read/28051242/a-pilot-study-about-the-oncologic-safety-of-colonic-self-expandable-metal-stents-sems-in-obstructive-colon-cancer-is-occlusion-always-better-than-silent-perforation
#14
A Zanghì, G Piccolo, A Cavallaro, E Pulvirenti, E Lo Menzo, F Cardì, M Di Vita, A Cappellani
OBJECTIVE: To evaluate the oncologic safety of colonic self-expandable metal stents (SEMS) in obstructive colon cancer. PATIENTS AND METHODS: We retrospectively reviewed all the patients who were treated with endoscopic placement of a self-expandable metallic stent (SEMS) at our institution. RESULTS: A total of 26 patients were identified during the study period, of which 24 patients (92.30%) were treated with SEMS as a bridge-to-surgery and 2 (7...
December 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28045715/oncologic-procedures-amenable-to-fluorescence-guided-surgery
#15
Kiranya E Tipirneni, Jason M Warram, Lindsay S Moore, Andrew C Prince, Esther de Boer, Aditi H Jani, Irene L Wapnir, Joseph C Liao, Michael Bouvet, Nicole K Behnke, Mary T Hawn, George A Poultsides, Alexander L Vahrmeijer, William R Carroll, Kurt R Zinn, Eben Rosenthal
OBJECTIVE: Although fluorescence imaging is being applied to a wide range of cancers, it remains unclear which disease populations will benefit greatest. Therefore, we review the potential of this technology to improve outcomes in surgical oncology with attention to the various surgical procedures while exploring trial endpoints that may be optimal for each tumor type. BACKGROUND: For many tumors, primary treatment is surgical resection with negative margins, which corresponds to improved survival and a reduction in subsequent adjuvant therapies...
December 30, 2016: Annals of Surgery
https://www.readbyqxmd.com/read/28035352/expression-of-ribophorine-ii-is-a-promising-prognostic-factor-in-human-gastric-adenocarcinoma
#16
Daisuke Fujimoto, Takanori Goi, Yasuo Hirono
The increased invasiveness of gastric adenocarcinoma is important for progression and metastasis. In recent molecular biological studies, ribophorine II (RPN2) induced epithelial-mesenchymal transition and metastatic activity. However, no studies have evaluated the relationship between RPN2 expression, ability of cancer to invade/metastasis, and patient prognosis in gastric adenocarcinoma. Therefore, we have examined these factors. Immunohistochemical staining was performed to detect RPN2 and p53 in the primary lesion and adjacent normal gastric mucosa of 242 gastric adenocarcinoma patients who underwent resection surgery...
February 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28035252/signet-ring-colorectal-carcinoma-do-we-need-to-improve-the-treatment-algorithm
#17
Anup Sunil Tamhankar, Parag Ingle, Reena Engineer, Munita Bal, Vikas Ostwal, Avanish Saklani
AIM: To elaborate about this peculiar variant from a tertiary cancer center from India. METHODS: It's a retrospective study (2011-2014) of all patients diagnosed with signet ring colo-rectal cancer (SRCC). Various clinico-pathological variables were studied. RESULTS: One hundred and seventy consecutive patients with SRCC were diagnosed (11.4% of all colorectal cancers). Median Age of the cohort was 41 years. Most common location was recto-sigmoid area (54...
December 15, 2016: World Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28032485/clinical-and-therapeutic-implications-of-aeromonas-bacteremia-14-years-nation-wide-experiences-in-korea
#18
Ji Young Rhee, Dong Sik Jung, Kyong Ran Peck
BACKGROUND: To elucidate the clinical presentation, antimicrobial susceptibility, and prognostic factors of monomicrobial Aeromonas bacteremia in order to determine the most effective optimal therapy. MATERIALS AND METHODS: We reviewed the medical records of Aeromonas bacteremia patients for the period January 2000 to December 2013 in a retrospective multi-center study. RESULTS: A total of 336 patient records were reviewed, with 242 having community-acquired bacteremia...
December 2016: Infection & Chemotherapy
https://www.readbyqxmd.com/read/28029523/cytoreduction-and-hyperthermic-intraperitoneal-chemotherapy-cs-hipec-in-colorectal-cancer-evidence-based-review-of-patient-selection-and-treatment-algorithms
#19
REVIEW
A H Maciver, N Lee, J J Skitzki, P M Boland, V Francescutti
Cytoreduction and heated intraperitoneal chemotherapy (CS/HIPEC) is increasingly utilized as a treatment strategy for patients with peritoneal metastases from various primary tumor sites. For this heterogenous procedure, related to patient characteristics, patient selection, and the extent of surgical completeness of cytoreduction, high level evidence (ex: multiple randomized controlled trials) is not available to support efficacy. This review of the available literature supporting application of the procedure, focusing on colorectal cancer, provides a summary of current evidence for patient selection and treatment algorithms based on patient presentation...
October 3, 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28029313/safety-and-activity-of-mirvetuximab-soravtansine-imgn853-a-folate-receptor-alpha-targeting-antibody-drug-conjugate-in-platinum-resistant-ovarian-fallopian-tube-or-primary-peritoneal-cancer-a-phase-i-expansion-study
#20
Kathleen N Moore, Lainie P Martin, David M O'Malley, Ursula A Matulonis, Jason A Konner, Raymond P Perez, Todd M Bauer, Rodrigo Ruiz-Soto, Michael J Birrer
Purpose This phase I expansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate consisting of a humanized anti-folate receptor alpha (FRα) monoclonal antibody linked to the tubulin-disrupting maytansinoid DM4, in a population of patients with FRα-positive and platinum-resistant ovarian cancer. Patients and Methods Patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer received IMGN853 at 6...
December 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
63801
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"